Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATIN-2 in Recent-Onset Type 1 Diabetes
NCT07610213Phase 1Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teplizumab, human insulin and aldesleukin in type 1 diabetes mellitus (T1D) (2 arms). Primary endpoint: Change in Stimulated C-peptide Area Under the Curve at 24 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
teplizumabhuman insulinaldesleukin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07610213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610213.